PureTech Health PLC is primarily active in the healthcare and life sciences industries. With a focus on developing innovative solutions for unmet medical needs, PureTech Health PLC invests in and nurtures cutting-edge start-ups within biotechnology, pharmaceuticals, and medical devices. By leveraging its expertise and network, the company aims to address major healthcare challenges and improve patient outcomes. Through its diverse portfolio of companies, PureTech Health PLC is committed to driving advancements and breakthroughs in various healthcare sectors, making a significant impact on the global healthcare landscape.

The main competitors of PureTech Health PLC in the market include pharma companies such as Johnson & Johnson, Pfizer Inc., Novartis AG, and AbbVie Inc. These companies operate in similar therapeutic areas and are involved in the development and commercialization of innovative healthcare products. PureTech Health PLC competes with these industry leaders by leveraging its unique pipeline and technology platforms to address unmet medical needs. As a global biopharmaceutical company, PureTech Health PLC strives to differentiate itself through breakthrough therapies and strategic partnerships to deliver value to patients, healthcare professionals, and shareholders.

PureTech Health PLC is a leading biopharmaceutical company with a diverse portfolio in the healthcare sector. Founded in 2002, PureTech focuses on developing innovative solutions to address significant medical challenges. The company operates with a unique research and development model that combines cutting-edge science, entrepreneurial expertise, and strategic partnerships to accelerate the delivery of transformative therapies. PureTech Health PLC is renowned for its commitment to advancing healthcare and improving patients' lives through its pioneering approach. With a track record of successful collaborations and a robust pipeline, the company continues to make significant contributions to the healthcare industry worldwide.

PureTech Health PLC has achieved several significant milestones. The company successfully launched its first product, Gelesis100, a weight loss therapy, in the United States. It also received FDA clearance for KarXT, a potential treatment for acute psychosis in schizophrenia and Alzheimer's disease. Additionally, PureTech Health secured strategic partnerships with renowned organizations like Novartis, Roche, and Bristol-Myers Squibb. These collaborations aim to advance innovative therapies in various therapeutic areas. The company has demonstrated strong clinical progress in its pipeline, including advancements in cancer immunotherapy, lymphatic targeting, and microbiome-based technologies. PureTech Health PLC continues to drive scientific advancements and partnerships to enhance patient care and address unmet medical needs.

PureTech Health PLC is primarily present in various countries and regions around the world. The company operates globally, with a strong presence in the United States, United Kingdom, and other key European markets. PureTech Health PLC is committed to advancing innovative healthcare solutions and collaborating with leading academic institutions, medical professionals, and industry partners internationally. Its global focus allows the company to tap into diverse markets and facilitate the development and commercialization of breakthrough therapies to improve patient outcomes.

PureTech Health PLC is a leading biotechnology company committed to advancing innovative solutions for unmet medical needs. With a strong emphasis on precision medicine, PureTech Health PLC believes in leveraging cutting-edge science and technology to develop transformative therapies. The company's corporate philosophy centers around collaboration, rigorous research, and patient-centricity. PureTech Health PLC aims to revolutionize healthcare by developing novel treatments for complex diseases, including neurological disorders, immune disorders, and gastrointestinal conditions. By integrating diverse expertise, the company strives to deliver meaningful outcomes and improve patients' lives. With a focus on breakthrough innovation, PureTech Health PLC is dedicated to driving positive change in the healthcare industry.

Analysts currently set an average price target of 701,64 USD for the PureTech Health stock (median: 701,64 USD), implying +40.188,4 % versus the latest price. The consensus is based on 5 analyst ratings.

PureTech Health Prezzi Obiettivo Analisti 2026

5 analysts currently rate the PureTech Health stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect PureTech Health to generate revenue of 10,76 Mio. USD and earnings per share of -0,54 USD.

PureTech Health Prezzi Obiettivo Analisti 2026

Converted at the current exchange rate, the PureTech Health share trades at 1,50 EUR (1,74 USD).

The PureTech Health share (PRTC.L) is listed on 4 stock exchanges, including: Frankfurt (0VQ.F), London (PRTC.L), London (PRTC.L).

PureTech Health PLC is a biopharmaceutical company that focuses on the development and commercialization of novel therapeutics. The company was founded in 2002 in the United Kingdom and is currently headquartered in Boston, USA. PureTech Health's business model is based on the identification of drug candidates that are developed based on the latest scientific knowledge. The company aims to translate innovative technologies and research findings into medical practice. PureTech Health specializes in the so-called "frontier sciences," which are research fields that have often not been sufficiently explored in regular academic research. PureTech Health consists of two main business segments: the discovery and development of drugs, and the launch and management of subsidiary companies that expand the company's product portfolio. The first business segment of PureTech Health focuses on identifying activity and intervention opportunities in biological systems. The company uses modern technologies and analyses to identify new indications and treatment possibilities. PureTech Health employs a combination of computer predictions, screening methods, proteomic analyses, and other modern tools to develop therapeutics that target specific targets in the body. The second main business segment of PureTech Health is the establishment and development of subsidiary companies specializing in the development of therapeutics in different indications. The subsidiary companies focus on specific health problems, such as pain therapy, neuropsychiatric disorders, or inflammation. One of PureTech Health's key products is the "Akili Interactive Labs" platform for the treatment of neurocognitive disorders. The platform utilizes gaming technology to enable targeted brain stimulation to improve cognitive abilities. The company has introduced the first digital drug candidate to the market and is considered a medical device by the FDA (U.S. Food and Drug Administration). Another subsidiary company of PureTech Health, Karuna Therapeutics, specializes in the treatment of psychiatric disorders. Karuna has obtained exclusive licensing rights to conduct clinical trials of Xanomeline, a drug with a novel mechanism of action that can be used to treat difficult psychiatric disorders such as schizophrenia. Furthermore, PureTech Health has established a strong network of universities and research institutions to integrate innovative technologies and findings from the natural sciences and technology into medical practice. The company pursues an open innovation strategy to leverage the latest research findings and continuously improve patient care. Overall, PureTech Health's business model is focused on strategic and selective project selection, combining cutting-edge scientific knowledge with a deep understanding of medical needs. The company has successfully demonstrated its ambitions to combine the value of good science with entrepreneurship.

Il attesa fatturato di PureTech Health ammonta a 10,76 Mio. USD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.

Il attesa profitto di PureTech Health ammonta a -137,17 Mio. USD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.

Il rapporto prezzo/utili (P/E) di PureTech Health è attualmente -3,25. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione PureTech Health.

Il rapporto prezzo/fatturato (P/S) di PureTech Health è attualmente 41,43. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione PureTech Health.

Il Quality Score AlleAktien per PureTech Health è 3/10.

L'ISIN di PureTech Health è GB00BY2Z0H74. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.

Il WKN di PureTech Health è A14VK6. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.

Il ticker di PureTech Health è PRTC.L. Con questo simbolo di borsa vengono negoziate le azioni PureTech Health in borsa.

PureTech Health ha pagato dividendi ogni anno negli ultimi 0 anni.

PureTech Health è assegnato al settore 'Sanità'.

I dividendi di PureTech Health sono distribuiti in USD.